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Abstract
Objective. Serum prealbumin is a recognized marker of malnutrition, but its role in the prognosis of
patients with SSc has not yet been investigated. The aim of the present multicentre prospective study
was to investigate the association between prealbumin and mortality, independent of clinical features, in a
cohort of SSc outpatients.
Methods. Patients were followed up according to standard clinical guidelines with visits at least every 6
months. Data collected included records of skin and internal organ involvement, survival and causes of
death.
Results. During a median follow-up of 48 months [interquartile range (IQR) 2558], 34/299 patients (11%)
died. In univariable survival analysis, age; male sex; lung, gastrointestinal or multiple visceral organ in-
volvement (two or more); co-morbidities (two or more) and low serum prealbumin were significant pre-
dictors of mortality. In bivariable Cox models, alternatively adjusted for significant predictors, prealbumin
was independently and significantly associated with the outcome. Mortality rates were particularly influ-
enced by low prealbumin in patients without significant co-morbidities or multiple organ involvement.
Conclusion. In SSc patients, low serum prealbumin is an independent predictor of mortality, particularly in
those without significant internal organ involvement. Further research on this nutritional marker is
warranted.
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Rheumatology key messages
. Low serum prealbumin predicts mortality in SSc independent of other significant risk factors.
. Mortality rates are influenced by prealbumin in SSc without significant co-morbidities or organ involvement.
. Interventional trials in SSc should establish the effect of modifying prealbumin status on mortality.
Introduction
Recent studies have shown that malnutrition is a frequent
co-morbidity in SSc, with a prevalence ranging from 15 to
55%, depending on the method of assessment and case
population. Several factors appear to contribute to this
picture, particularly gastrointestinal symptoms, disease
subset, activity or disability [13]. The negative prognostic
impact of malnutrition in acute and chronic diseases is
well established [4], but evidence in SSc is still limited.
Krause et al. [1] recently found that the impairment of
body composition predicts survival; in their study, how-
ever, the independent prognostic value of nutritional de-
rangements was not investigated in combination with
other predictors. Changes in body composition are likely
to reflect disease severity and activity and potential inter-
actions between these components in outcome prediction
could not be excluded. Also, the combined assessment of
nutritional parameters and disease activity was shown to
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improve the evaluation of mortality risk in SSc [5]. Our
group recently showed that serum prealbumin is a
marker of malnutrition in SSc [3], but its role in the prog-
nosis has not yet been investigated. The aim of the pre-
sent prospective study was to investigate the association
between prealbumin and mortality, independent of clinical
features, in a cohort of SSc outpatients.
Methods
Study design
We report the analysis of a multicentre cohort study of
outpatients affected by SSc followed at two University
Hospitals: IRCCS Policlinico San Matteo Foundation
(Pavia, Italy) and Spedali Civili Hospital (Brescia, Italy).
Part of the Pavia cohort (n= 160) has been previously ana-
lysed in both cross-sectional and prospective studies [3,
5]. In brief, all consecutive SSc patients satisfying LeRoy’s
criteria for SSc [6] attending the outpatient clinics of the
Rheumatology Unit of both institutions from September
2006 to September 2012 were screened for study inclu-
sion. Exclusion criteria were patient’s refusal, age <18
years and acute complications. All patients underwent a
complete clinical assessment and serum collection. Data
included demography (sex and age), age at onset (date of
the first non-Raynaud’s symptom), disease duration, lim-
ited/diffuse disease subset (LeRoy’s criteria) [6], modified
Rodnan skin score, visceral involvement (according to the
EULAR Scleroderma Trials and Research group recom-
mendations) [7], disease activity (active disease was
defined as a score 53) [8] and other co-morbidities.
Finally, fasting (812 h in post-absorptive state) venous
blood samples were drawn for full investigation of the
autoantibody profile (EliA, Phadia, Germany) and the as-
sessment of serum prealbumin (immunonephelometric
method; Dade Behring, Eschborn, Germany). Reduced
prealbumin serum levels were defined as values
<200 mg/l [9]. Anthropometric nutritional parameters
(BMI and weight loss), which were already investigated
by our group [3, 5], were not included in the present ana-
lysis due to colinearity with serum prealbumin. The multi-
centre cohort study was approved by the local
institutional ethics committees (IRCCS Policlinico San
Matteo Foundation and Comitato Etico Provinciale della
Provincia di Brescia) and written informed consent was
obtained. Ethical approval for the cohort was extended
to include this subanalysis.
Statistical analysis
Patient survival was defined as the time between the date
of enrolment and the date of death from any cause or the
date of last contact or last known to be alive.
KaplanMeier cumulative survival was computed. The
Cox proportional hazard model was used to evaluate
non-collinear predictors of death. Associations between
mortality and clinical features and prealbumin were initially
investigated in univariable models. Then, multivariable
analysis was used to control the effect of prealbumin for
other known clinical risk factors. The effect modification of
prealbumin by clinical features was assessed with a test
on interaction. The Harrell’s C statistic was computed for
model validation. Hazard ratios (HRs) and their 95% CIs
were computed, as well as the incidence rate per 100
patients/year. A two-sided P-value <0.05 was deemed
to be significant. All statistical analyses were performed
using STATA 13.1 statistical software (StataCorp, College
Station, TX, USA).
Results
In this multicentre study, a total of 299 patients with SSc
were enrolled: 239 at the Rheumatology Unit in Pavia and
60 in Brescia. The demographic and clinical characteris-
tics of the population are presented in Table 1.
After a median follow-up of 48 months [interquartile
range (IQR) 2558], 34 patients (11%) had died. Causes
of death were SSc-related causes [n= 30; 28 with pulmon-
ary complications (fibrosis or pulmonary hypertension)
and 2 with severe gastrointestinal involvement], neoplastic
complications (n= 3; 2 lung and 1 oesophageal carcin-
omas) and hepatic cirrhosis (n= 1). In the univariable ana-
lysis (Table 1), age, male sex, lung and gastrointestinal
involvement, presence of multiple (two or more) visceral
organ involvement, presence of co-morbidities (two or
more) and low serum prealbumin were significant pre-
dictors of mortality, with higher HRs for lung or multiple
visceral organ involvement [5 (95% CI 2.45, 10.34) and
3.94 (2.01, 7.74), respectively; both P< 0.0001].
Due to the relatively small number of events, no multi-
variable analysis could be performed and relevant SSc
clinical predictors in univariable analysis were alternatively
included in bivariable models in order to test the inde-
pendent association between serum prealbumin and mor-
tality (Table 2). In models alternatively adjusted for single
factors (age; male sex; lung or gastrointestinal involve-
ment; multiple visceral organ involvement and two or
more co-morbidities, including kidney or hepatic failure;
HCV infection and autoimmune hypothyroidism; medica-
tion with steroids or NSAIDs), low serum prealbumin re-
tained a significant association with mortality. In
particular, it was the only significant predictor when com-
bined with demographic parameters (age and sex), HCV
infection, medications and gastrointestinal involvement. In
the other models, both prealbumin and either multiple co-
morbidities, lung involvement or multiple visceral organ
involvement were independently associated with death.
Mortality rates (per 100 patients/year) in pre-specified
groups by disease predictors and prealbumin are also
shown in Table 2. Again, models with the best fit (and
higher Harrell’s C statistics) were those including lung or
multiple visceral organ involvement [Harrell’s C 0.76 (95%
CI 0.68, 0.84) and 0.75 (0.660.83), respectively].
Discussion
The present multicentre study shows that serum prealbu-
min is a predictor of mortality in SSc patients independent
of other significant disease-related risk factors. These
findings support the importance of the nutritional domain
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and the need to assess nutritional status and its bio-
markers in every SSc patient. Malnutrition is not uncom-
mon in SSc [13]. Furthermore, its presence has been
strongly associated with active disease and low serum
prealbumin levels [3]. BMI alone was found to be unre-
lated to mortality, while impaired nutritional status accord-
ing to body composition analysis was found to predict
mortality [1]. Also, the combined assessment of nutritional
parameters and disease activity was shown to improve
the evaluation of mortality risk [5]. However, the independ-
ent association between nutritional derangements and
mortality has never been an object of investigation. In
the present study, low serum prealbumin conferred ele-
vated HRs in the survival analysis, which remained statis-
tically significant even after adjusting for other known risk
factors in SSc. An association between reduced prealbu-
min and adverse outcomes has been detected in several
other chronic diseases [911], but this is the first report to
describe it in SSc.
Serum prealbumin is reasonably considered a nutri-
tional marker. However, many conditions appear to
affect its serum levels, such as protein-calorie intake,
organ dysfunction (e.g. liver or kidney), medications
(glucocorticoids and/or high-dose NSAIDs), hormonal dis-
orders (e.g. hypothyroidism) and inflammation, differently
and synergistically acting on the balance between synthe-
sis and catabolism [12, 13]. With respect to SSc, it is rea-
sonable to believe that prealbumin mirrors the status of
body protein stores and the metabolically active compo-
nents of the body, which in turn are likely to be affected by
chronic low-grade inflammation [14] and have been asso-
ciated with outcome more strongly than BMI [15].
However, although no association was found between
prealbumin levels and most of the aforementioned factors,
including ESR (data not shown), we were unable to fully
explore this hypothesis. We did not collect information on
CRP levels or abnormal liver disease and it would be inter-
esting to investigate how these parameters correlate with
prealbumin and compare to it in predicting outcome. Our
population showed a low median disease activity score
and it is likely that CRP levels were low in this sample,
which is probably not powered enough to rule out the
influence of CRP alone on the outcome or in combination
with other predictors. Furthermore, mortality was unre-
lated to disease activity in our study. On the other hand,
despite the fact that models with the best fit (higher
Harrell’s C statistic) were those including prealbumin
and lung or multiple visceral organ involvement, in our
analysis, rates of mortality were especially influenced by
prealbumin levels in patients without significant organ in-
volvement or co-morbidities, drawing attention to a poten-
tial underestimation of the prognosis in the absence of a
severe and co-morbid clinical picture. Indeed, there was a
striking difference (more than 3-fold in both cases) among
incidence rates of mortality in those without significant
organ involvement or with no or just one co-morbidity
but with different prealbumin concentrations (>200 mg/l
or <200 mg/l), arguing in favour of the added value of
prealbumin in these cases and their prognostic stratifica-
tion. Importantly, prealbumin levels are subject to change
TABLE 1 Demographic, clinical and nutritional characteristics of the population with univariable HR for mortality
Characteristic Population (n= 299) Univariable HR (95% CI) P-value
Age, mean (S.D.), years 61 (11.8) 3.49 (1.62, 7.54) 0.001
Male, n (%) 39 (13) 3.68 (1.68, 8.03) 0.001
Disease duration, median (IQR), months 77 (13118) 1.06 (0.85, 1.3) 0.617
Disease subset (diffuse), n (%) 51 (17) 1.31 (0.57, 3) 0.523
Skin thickness (mRSS), median &nbsp;(IQR) 7 (210) — —
DAS (010), median (IQR) 1.5 (0.52.5) 1.13 (0.94, 1.36) 0.207
Active disease (score 53), n (%) 54 (18) 1.98 (0.94, 4.17) 0.071
Serologic pattern
Anti-centromere positive, n (%) 164 (55) 0.70 (0.26, 1.87) 0.476
Anti-topoisomerase-I positive, n (%) 49 (16) 2.43 (0.93, 6.32) 0.069
Other, n (%)&nbsp; 78 (26) 1.5 (0.52, 4.28) 0.454
Negative, n (%)&nbsp; 7 (2)
Lung involvement, n (%) 94 (31) 5 (2.45, 10.34) 40.001
Gastrointestinal involvement, n (%)&nbsp; 166 (56) 2.15 (1.03, 4.5) 0.043
Kidney involvement, n (%) 9 (3) 1 (0.14, 7.3) 0.997
Multiple visceral organs involvement (52), n (%) 69 (23) 3.94 (2.01, 7.74) 40.001
Co-morbidities 0.025
None, n (%) 135 (45)
1, n (%) 119 (39) 2.26 (0.96, 5.32) 0.06
52, n (%) 48 (16) 3.42 (1.35, 8.7) 0.01
Prealbumin, mean (S.D.), mg/l 259 (140)
<200 mg/l, n (%) 58 (20) 3 (1.52, 5.97) 0.002
Disease activity has been calculated according to the criteria defined by the European Scleroderma Study Group [8] (score
010). HR: hazard ratio; IQR: interquartile range; mRSS: modified Rodnan skin score.
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with nutritional interventions [16], and nutritional support
may be effective in improving not only nutritional status,
but also patient outcome [17].
The main limitation of our longitudinal study is the small
number of events that occurred during the follow-up, a
factor that clearly hampers the statistical power of our
analyses. It could not be excluded that a larger sample
size and a longer follow-up would allow identification of an
even stronger independent prognostic value of serum pre-
albumin. In this view, prealbumin probably represents a
more sensitive serological nutrition-related biomarker,
offering a reliable prognostic stratification of SSc patients.
Another limitation of our study is that the effect of vari-
ables acting during the follow-up has not been con-
sidered. The possibility of nutritional interventions
altering prealbumin status and possibly positively influen-
cing the prognosis remains to be evaluated with a specific
trial. Finally, evidence is confined to SSc patients.
In conclusion, low serum prealbumin seems a useful
prognostic marker in SSc patients, independent of estab-
lished clinical factors. Therefore we suggest further re-
search on this parameter and that nutritional
assessment should be part of the clinical workup of
every SSc patient. Thus clinical nutrition trials are war-
ranted in order to investigate the role of nutritional support
on patient’s outcome.
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